Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 3
1996 8
1997 3
1998 4
1999 4
2000 3
2001 5
2002 9
2003 6
2004 6
2005 5
2006 4
2007 3
2008 4
2009 4
2010 14
2011 8
2012 11
2013 16
2014 17
2015 7
2016 15
2017 26
2018 25
2019 21
2020 12
2021 30
2022 25
2023 28
2024 42
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.
Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting.
Nadim MK, Kellum JA, Forni L, Francoz C, Asrani SK, Ostermann M, Allegretti AS, Neyra JA, Olson JC, Piano S, VanWagner LB, Verna EC, Akcan-Arikan A, Angeli P, Belcher JM, Biggins SW, Deep A, Garcia-Tsao G, Genyk YS, Gines P, Kamath PS, Kane-Gill SL, Kaushik M, Lumlertgul N, Macedo E, Maiwall R, Marciano S, Pichler RH, Ronco C, Tandon P, Velez JQ, Mehta RL, Durand F. Nadim MK, et al. Among authors: pichler rh. J Hepatol. 2024 Jul;81(1):163-183. doi: 10.1016/j.jhep.2024.03.031. Epub 2024 Mar 26. J Hepatol. 2024. PMID: 38527522 Free PMC article. Review.
Editorial: Immune checkpoint inhibitors in renal cell carcinoma.
Tykodi SS, Pichler R. Tykodi SS, et al. Among authors: pichler r. Front Oncol. 2023 Apr 18;13:1203463. doi: 10.3389/fonc.2023.1203463. eCollection 2023. Front Oncol. 2023. PMID: 37143949 Free PMC article. No abstract available.
Drug-Drug Interactions in Prostate Cancer Treatment.
Hebenstreit D, Pichler R, Heidegger I. Hebenstreit D, et al. Among authors: pichler r. Clin Genitourin Cancer. 2020 Apr;18(2):e71-e82. doi: 10.1016/j.clgc.2019.05.016. Epub 2019 May 27. Clin Genitourin Cancer. 2020. PMID: 31677899 Review.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C. Santoni M, et al. Among authors: pichler r. Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21. Eur Urol Oncol. 2024. PMID: 37481365
Terlipressin: Hopes Fulfilled or Dashed?
Pichler RH, Swenson ER, Leary PJ, Paine CH. Pichler RH, et al. Clin J Am Soc Nephrol. 2022 Jan;17(1):140-142. doi: 10.2215/CJN.06710521. Epub 2021 Nov 17. Clin J Am Soc Nephrol. 2022. PMID: 34789475 Free PMC article. No abstract available.
Glomerular healing.
Johnson RJ, Pichler R, Hugo C, Nangaku M, Savill J, Alpers CE. Johnson RJ, et al. Among authors: pichler r. Contrib Nephrol. 1996;118:54-8. doi: 10.1159/000425076. Contrib Nephrol. 1996. PMID: 8744040 Review. No abstract available.
Albumin in Cirrhosis: More Than a Colloid.
Paine CH, Biggins SW, Pichler RH. Paine CH, et al. Among authors: pichler rh. Curr Treat Options Gastroenterol. 2019 Jun;17(2):231-243. doi: 10.1007/s11938-019-00227-4. Curr Treat Options Gastroenterol. 2019. PMID: 30968341 Review.
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.
Noeraparast M, Krajina K, Pichler R, Niedersüß-Beke D, Shariat SF, Grünwald V, Ahyai S, Pichler M. Noeraparast M, et al. Among authors: pichler r. Cancer Commun (Lond). 2024 Oct;44(10):1189-1208. doi: 10.1002/cac2.12602. Epub 2024 Aug 19. Cancer Commun (Lond). 2024. PMID: 39161208 Free PMC article. Review.
327 results